PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Bromates”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Review of the methods of the US Environmental Protection Agency for bromate determination and validation of method 317.0 for disinfection by-product anions and low-level bromate.

In recent years several methods have been published by the United States Environmental Protection Agency (EPA) which specify bromate as a target analyte. The first of these was EPA Method 300.0. As technological improvements in ion chromatographic hardware have evolved and new detection techniques have been designed, method detection limits for bromate have been reduced and additional procedures have been written, including EPA Method 300.1, 321.8 and, most recently, EPA Method 317.0. An overview of the evolution of these bromate methods since 1989 is presented. The focus is specific to each of these respective procedures, highlighting method strengths, weaknesses, and addressing how these methods fit into EPA's regulatory agenda. In addition, performance data are presented detailing the joint EPA/American Society for Testing and Materials multilaboratory validation of EPA Method 317.0 for disinfection by-product anions and low-level bromate.

Anions↗

A review of the effects of bromate on aquatic organisms and toxicity of bromate to oyster (Crassostrea gigas) embryos.

A critical literature review has been undertaken of the effects that bromate (BrO3-) has on aquatic organisms. Chronic (multigeneration) studies using four marine phytoplankton species indicate a stimulation of cell division at concentrations up to 13.6 mg BrO3- liter-1, such that the EC50 is > 13.6 mg BrO3- liter-1 (exposure period unspecified). No published data were available for any freshwater algal or phytoplankton species. For freshwater invertebrates, the available data are limited to acute studies using two species: the water flea, Daphnia magna, with a 48-h LC50 of 179 mg BrO3- liter-1; and the planarian ("flatworm"), Polycelis nigra, with a 48-h LC50 of 2258 mg BrO3- liter-1. For saltwater invertebrates, there is a greater variety in the spread of species sensitivity to bromate. For crustaceans, the lowest reported acute value is a 24-h LC50 of 176 mg BrO3- liter-1 for mysid shrimp. For molluscs, the published data are somewhat contradictory, with different workers reporting EC50 values to oyster embryo-larvae of either 0.05-0.1 or 30 mg BrO3- liter-1. Following repeated attempts to resolve these differences using the Pacific oyster (Crassostrea gigas) embryo development assay, a 24-h EC50 of 170 mg BrO3- liter-1 was observed. Reported 96-h LC50 values for juvenile saltwater fish range from 427 to 512 mg BrO3- liter-1, while a 10-day LC50 of 279 mg BrO3- liter-1 is also reported. For fish early lifestages, newly hatched larvae are more sensitive than embryo hatching, with a larval 96-h LC50 of 31 mg BrO3- liter-1 being observed. Less severe effects have been reported for older larvae (pro-larvae), for which a 96-h LC50 of 404 mg BrO3- liter-1 is reported. In conclusion, a number of studies provide evidence for the acute toxicity of bromate to invertebrates and fish in the lowest region of 30 mg BrO3- liter-1. Applying the factor of 10 used to extrapolate from acute to potential chronic toxicity, the available data suggest that to protect aquatic organisms from long-term adverse effects, concentrations should not exceed approximately 3.0 mg BrO3- liter-1.

Animals↗

Water quality factors affecting bromate reduction in biologically active carbon filters.

Biological removal of the ozonation by-product, bromate, was demonstrated in biologically active carbon (BAC) filters. For example, with a 20-min EBCT, pH 7.5, and influent dissolved oxygen (DO) and nitrate concentrations 2.1 and 5.1 mg/l, respectively, 40% bromate removal was obtained with a 20 microg/l influent bromate concentration. In this study, DO, nitrate and sulfate concentrations, pH, and type of source water were evaluated for their effect on bromate removal in a BAC filter. Bromate removal decreased as the influent concentrations of DO and nitrate increased, but bromate removal was observed in the presence of measurable effluent concentrations of DO and nitrate. In contrast, bromate removal was not sensitive to the influent sulfate concentration, with only a slight reduction in bromate removal as the influent sulfate concentration was increased from 11.1 to 102.7 mg/l. Bromate reduction was better at lower pH values (6.8 and 7.2) than at higher pH values (7.5 and 8.2), suggesting that it may be possible to reduce bromate formation during ozonation and increase biological bromate reduction through pH control. Biological bromate removal in Lake Michigan water was very poor as compared to that in tapwater from a groundwater source. Bromate removal improved when sufficient organic electron donor was added to remove the nitrate and DO present in the Lake Michigan water, indicating that the poor biodegradability of the natural organic matter may have been limiting bromate removal in that water. Biological bromate removal was demonstrated to be a sustainable process under a variety of water quality conditions, and bromate removal can be improved by controlling key water quality parameters.

Bromates↗

Bromate in chlorinated drinking waters: occurrence and implications for future regulation.

Bromate is a contaminant of commercially produced solutions of sodium hypochlorite used for disinfection of drinking water. However, no methodical approach has been carried out in U.S. drinking waters to determine the impact of such contamination on drinking water quality. This study utilized a recently developed method for quantitation of bromate down to 0.05 microg/L to determine the concentration of bromate present in finished waters that had been chlorinated using hypochlorite. Forty treatment plants throughout the United States using hypochlorite in the disinfection step were selected and the levels of bromate in the water both prior to and following the addition of hypochlorite were measured. The levels of bromate in the hypochlorite feedstock were also measured and together with the dosage information provided by the plants and the amount of free chlorine in the feedstock, it was possible to calculate the theoretical level of bromate that would be imparted to the water. A mass balance was performed to compare the level of bromate in finished drinking water samples to that found in the corresponding hypochlorite solution used for treatment. Additional confirmation of the source of elevated bromate levels was provided by monitoring for an increase in the level of chlorate, a co-contaminant of hypochlorite, atthe same point in the treatment plant where bromate was elevated. This study showed that bromate in hypochlorite-treated finished waters varies across the United States based on the source of the chemical feedstock, which can add as much as 3 microg/L bromate into drinking water. Although this is within the current negotiated industry standard that allows up to 50% of the maximum contaminant level (MCL) for bromate in drinking water to be contributed by hypochlorite, it would be a challenge to meet a tighter standard. Given that distribution costs encourage utilities to purchase chemical feedstocks from local suppliers, utilities in certain regions of the United States may be put at a distinct disadvantage if future lower regulations on bromate levels in finished drinking water are put into place. Moreover, with these contaminant levels it would be almost impossible to lower the maximum permissible contribution to bromate in finished water from hypochlorite to 10% of the MCL, which is the norm for other treatment chemicals. Until this issue is resolved, it will be difficult to justify a lowering of the bromate MCL from its current level of 10 to 5 microg/L or lower.

Bromates↗

Bromate analysis in groundwater and wastewater samples.

Bromate (BrO(3)(-)) is a disinfection by-product formed during ozonation of potable water supplies containing bromide (Br(-)). Bromate has been classed by the World Health Organisation as a 'possible human carcinogen', leading to implementation of 10-25 microg L(-1)(as BrO(3)(-)) drinking water limits in legislative areas including the United States and European Union. Techniques have been developed for bromate analysis at and below regulatory limits, with Ion Chromatography (IC) coupled with conductivity detection (IC-CD), post-column reaction and ultra-violet (UV) detection (IC-PCR), or inductively coupled plasma-mass spectrometry detection (IC-ICPMS) in widespread use. The recent discovery of bromate groundwater contamination in a UK aquifer has led to a requirement for analysis of bromate in a groundwater matrix, for environmental monitoring and development of remediation strategies. The possibility of bromate-contaminated water discharge into sewage treatment processes, whether accidental or as a pump-and-treat strategy, also required bromate analysis of wastewater sources. This paper summarises techniques currently available for trace bromate analysis in potable water systems and details studies to identify a methodology for routine analysis of groundwater and wastewater samples. Strategies compared were high performance liquid chromatography (HPLC) with direct UV or PCR/UV detection, IC-CD, IC-PCR, and a simple spectrophotometric technique. IC-CD was the most cost-effective solution for simultaneous analysis of bromate and bromide within groundwater samples, having a 5 microg L(-1) detection limit of both anions with limited interference from closely-eluting species. Wastewater samples were successfully analysed for bromate only using HPLC with PCR/UV detection, with detection limits below 20 microg L(-1)(as BrO(3)(-)) and low interference. HPLC with direct UV detection was unsuitable for bromate analysis within the concentration range 50-5000 microg L(-1) which was required for this project, but column choice was shown to be a major factor in determining limits of detection. Spectrophotometry could not reproducibly determine bromate concentration, although the technique showed promise as a quick field method for high-level groundwater bromate analysis.

Bromates↗

Cometabolic reduction of bromate by a mixed culture of microorganisms using hydrogen gas in a gas-lift reactor.

The discharge of bromate, a suspected carcinogen, will be restricted in the near future. To assess the possibility of biotechnological treatment of bromate-containing wastewaters, the removal of bromate by chlorate-reducing microorganisms was studied. The removal of bromate and chlorate was studied in laboratory gas-lift bioreactors supplied with hydrogen gas as electron donor in the absence of molecular oxygen. In these reactors, bromate was reduced cometabolically by chlorate-respiring microorganisms. To allow the cometabolic reduction of bromate, a chlorate:bromate molar ratio of at least 3:1 was required. The cometabolic conversion permitted almost complete reduction of bromate into bromide at hydraulic retention times of at least 6 h. Optimal bromate reduction activity was observed at approximately 35 degrees C. The pH optimum was between 7 and 8. Bromate reduction in excess of 80% and a maximum bromate reduction rate of 2.3 g l(-1) day(-1) in a pilot-scale gas-lift bioreactor demonstrates that the process is sustainable.

Air Pollutants↗

The effects of operational parameters and common anions on the reactivity of zero-valent iron in bromate reduction.

Bromate reduction by Fe(0) was investigated under various conditions in batch tests. The bromate was primarily reduced to bromide ions with possible adsorption onto iron. Bromate reduction by Fe(0) can be described by pseudo-first-order kinetics. The differences in surface areas, numbers of reactive sites, impurities, pretreatment methods and numbers of repeated uses of iron affected the rates of bromate reduction through reducing or accumulating a passive oxide film on the iron surface. The reduction of bromate was significantly affected by only the dissolved oxygen content at supersaturated concentrations or by decreasing the pH from 6 to 5. Increasing the temperature increased the bromate reduction rate, which followed the Arrhenius relationship with activation energy of 52.6 kJmol(-1) and the reduction rate increased with increased mixing rates. These observations indicate that bromate reduction by iron is a surface-mediated process and diffusion to the surface is essential. Under the test conditions, modest inhibitory effects on bromate reduction by Fe(0) from nitrite, chlorate and bicarbonate were observed and the inhibitory effect from phosphate was relatively larger. Enhanced reactivity of Fe(0) to bromate was observed in the presence of nitrate or sulfate. These findings suggest that bromate reduction by Fe(0) can be an effective method for bromate control.

Anions↗

Analysis of bromate and bromide in blood.

Bromate is a regulated disinfection byproduct primarily associated with the ozonation of water containing bromide, but also is a byproduct of hypochlorite used to disinfect water. To study the pharmacokinetics of bromate, it is necessary to develop a robust and sensitive analytical method for the identification and quantitation of bromate in blood. A critical issue is the extent to which bromate is degraded presystemically and in blood at low (environmentally relevant) doses of ingested bromate as it is delivered to target tissue. A simple isolation procedure was developed using blood plasma spiked with various levels of bromate and bromide. Blood proteins and lipids were precipitated from plasma using acetonitrile. The resulting extracts were analyzed by ion-chromatography with inductively-coupled plasma mass spectrometry (IC-ICP/MS), with a method reporting limit of 5 ng/mL plasma for both bromate and bromide. Plasma samples purchased commercially were spiked with bromate and stored up to 7 days. Over the 7 day storage period, bromate decay remained under 20% for two spike doses. Decay studies in plasma samples from spiked blood drawn from live rats showed significant bromate decay within short periods of time preceding sample freezing, although samples which were spiked, centrifuged and frozen immediately after drawing yielded excellent analytical recoveries.

Bromates↗

Bromate: concern for developmental neurotoxicity?

The use of ozonation in the purification of drinking water can lead to the formation of bromate. The current regulatory challenges for bromate contamination of drinking water include the need to assess potential human health risks. One health risk of concern is developmental neurotoxicity. Currently, the need for a developmental neurotoxicity study for bromate, based on the weight of evidence, is uncertain. Bromate induces neurotoxicity in adults at high acute exposures and produces hearing loss and structural damage in the cochlea in humans and rodents. However, there is a wide margin of exposure in these studies compared to environmental levels of bromate in water supplies. Data on the effects of bromate on thyroid hormone levels is not consistent and thyroid endocrine disruption is not likely a causative factor in thyroid tumor formation. There is no evidence that bromate caused central nervous system malformations, brain weight changes in developmental studies, nor are there any known structure-activity relationships to other known neurotoxicants. A prudent approach to reduce the uncertainty in the need for a developmental neurotoxicity study of exposure to bromate in drinking water should include determinations of whether bromate ototoxicity occurs with extended duration, low concentration exposures. These studies would provide invaluable data for the weight-of-evidence approach used to determine the necessity of a developmental neurotoxicity study of bromate.

Animals↗

Development of a rat dosimetry model for bromate.

Bromate is a known animal carcinogen that is found in drinking water supplies treated with ozone. Bromate targets the kidney for toxicity and cancer, the peritoneum for cancer (mesotheliomas derived from testes), testes for lowered sperm count and the thyroid for follicular cell cancer. Kidney tumors as well as other toxicities may be caused by the metabolism of bromate to reactive intermediates. There is evidence that bromate and its stable metabolite bromide are actively transported by the sodium iodide transporter (NIS) protein found in the thyroid, kidney and testes. This association strongly suggests that characterizing the preferential distribution of bromate into the NIS-rich tissues and its subsequent metabolism to reactive metabolites is important for interpreting the dose-response characteristics of bromate in rodents. In this paper the current evidence for NIS dependent dosimetry for bromate is developed and studies are proposed to develop a physiologically based pharmacokinetic (PBPK) model for bromate. The recent PBPK models describing NIS protein transport of perchlorate and radiolabeled iodide offer a template for the development of the bromate model in rodents and humans. The proposed research is expected to be instrumental in quantifying the human health risks associated with ingestion of low levels of bromate in drinking water.

Animals↗

Experimental results from the reaction of bromate ion with synthetic and real gastric juices.

This study was designed to identify and quantify the effects of reducing agents on the rate of bromate ion reduction in real and synthetic gastric juice. This could be the first element in the sequence of a pharmacokinetic description of the fate of bromate ion entering the organism, being metabolized, and subsequently being tracked through the system to the target cell or eliminated. Synthetic gastric juice containing H+ and Cl- did exhibit reduced bromate ion levels, but at a rate that was too slow for a significant amount of bromate to be reduced under typical stomach retention time conditions. The reaction orders for Cl- and H+ were 1.50 and 2.0, respectively. Addition of the reducing agents hydrogen sulfide (which was shown to be present and quantified in real gastric juice), glutathione, and/or cysteine increased the rate of bromate ion loss. All of the reactions showed significant pH effects. Half-lives as short as 2 min were measured for bromate ion reduction in 0.17 M H+ and Cl- and 10(-4) M H2S. Therefore, the lifetime of bromate ion in solutions containing typical gastric juice concentrations of H+, Cl-, and H2S is 20-30 min. This rate should result in as much as a 99% reduction of bromate ion during its residence in the stomach. Bromate ion reduction in real gastric juice occurred at a rapid rate. A comparison of real and synthetic gastric juice containing H+, Cl-, cysteine, glutathione, and hydrogen sulfide showed that the component most responsible for the considerable decrease of the concentration of bromate ion in the stomach is hydrogen sulfide.

Bromates↗

Reduction of bromate to bromide coupled to acetate oxidation by anaerobic mixed microbial cultures.

Bromate, a weakly mutagenic oxidizing agent, exists in surface waters. The biodegradation of bromate was investigated by assessing the ability of mixed cultures of micro-organisms for utilization of bromate as electron acceptor and acetate as electron donor. Reduction of bromate was only observed at relatively low concentrations (<3.0 mM) in the absence of molecular oxygen. Under these conditions bromate was reduced stoichiometrically to bromide. Unadapted sludge from an activated sludge treatment plant and a digester reduced bromate without lag period at a constant rate. Using an enrichment culture adapted to bromate, it was demonstrated that bromate was a terminal electron acceptor for anaerobic growth. Approximately 50% of the acetate was utilized for growth with bromate by the enrichment culture. A doubling of 20 h was estimated from a logarithmic growth curve. Other electron acceptors, like perchlorate, chlorate and nitrate, were not reduced or at negligible rates by bromate-utilizing microorganisms.

Acetates↗

Isotope dilution analysis of bromate in drinking water matrixes by ion chromatography with inductively coupled plasma mass spectrometric detection.

Bromate is a disinfection byproduct in drinking water which is formed during the ozonation of source water containing bromide. This paper describes the analysis of bromate via ion chromatography-inductively coupled plasma mass spectrometry. The separation of bromate from interferences such as bromide and brominated haloacetic acids is achieved using a PA-100 column in combination with a 5 mM HNO3 + 25 mM NH4NO3 mobile phase. Polyatomic ions are observed on masses 79 and 81 in a synthetic phosphate matrix and in ozonated drinking waters. These polyatomic ions have been tentatively identified as PO3+ and H2PO3+. These polyatomic ions do not interfere with the detection of bromate because phosphate elutes prior to bromate. A polyatomic ion is observed on mass 81 in a synthetic sulfate matrix and in ozonated drinking waters. This polyatomic ion has been tentatively identified as HSO3+ and does not interfere with the detection of bromate because sulfate elutes after bromate. Isotope dilution analysis produces a relative standard deviation (RSD) of approximately 5% for both enriched isotopic additions at sample concentrations of 10 ng/g. The RSD associated with the direct analysis of bromate is 3.2% at sample concentrations of 10 ng/g. The bromate concentrations determined in ozonated drinking waters via isotope dilution analysis are within 10% of the concentrations determined via direct analysis for sample concentrations above 2 ng/g. The detection limit for the direct analysis of bromate via IC-ICPMS is 0.3 ng/g.

Bromates↗

Research strategy for developing key information on bromate's mode of action.

Bromate is produced when ozone is used to treat waters that contain trace amounts of bromide ion. It is also a contaminant of hypochlorite solutions produced by electrolysis of salt that contains bromide. Both ozone and hypochlorite are extensively used to disinfect drinking water, a process that is credited with reducing the incidence of waterborne infections diseases around the world. In studies on experimental animals, bromate has been consistently demonstrated to induce cancer, although there is evidence of substantial species differences in sensitivity (rat>mouse>hamster). There are no data to indicate bromate is carcinogenic in humans. An issue that is critical to the continued use of ozone as a disinfectant for drinking water in bromide-containing waters depends heavily on whether current predictions of carcinogenic risk based on carcinogenic responses in male rats treated with bromate are accurate at the much lower exposure levels of humans. Thiol-dependent oxidative damage to guanine in DNA is a plausible mode of action for bromate-induced cancer. However, other mechanisms may contribute to the response, including the accumulation of alpha2u-globulin in the kidney of the male rat. To provide direction to institutions that have an interest in clarifying the toxicological risks that bromate in drinking water might pose, a workshop funded by the Awwa Research Foundation was convened to lay out a research strategy that, if implemented, could clarify this important public health issue. The technical issues that underlie the deliberations of the workshop are provided in a series of technical papers. The present manuscript summarizes the conclusions of the workgroup with respect to the type and timing of research that should be conducted. The research approach is outlined in four distinct phases that lay out alternative directions as the research plan is implemented. Phase I is designed to quantify pre-systemic degradation, absorption, distribution, and metabolism of bromate and to associate these with key events for the induction of cancer and develop an initial pharmacokinetic (PK) model based on preliminary studies. Phase II will be implemented if it appears that there is a linear relationship between external dose and key event responses and is designed to gather carcinogenesis data in female rats in the absence of alpha2u-globulin-induced nephropathy which the workgroup concluded was a probable contributor to the responses observed in the male rats for which detailed dose-response data were collected. If the key events and external dosimetry are found not to be linear in Phase I, Phase III is initiated with a screening study of the auditory toxicity of bromate to determine if it is likely to be exacerbated by chronic exposure. If this occurs, auditory toxicity will be further evaluated in Phase IV. If auditory toxicity is determined unlikely to occur, an alternative chronic study in female rats to the one identified in Phase II will be implemented to include exposure in utero. This was recommended to address the possibility that the fetus may be more susceptible. One of the three options are to be implemented in Phase IV depending upon whether preliminary data indicated that chronic auditory toxicity, reproductive and/or developmental toxicities, or a combination of these outcomes is necessary to characterize the toxicology of low dose exposures to bromate. Each phase of the research will be accompanied by further development of pharmacokinetic models to guide collection of appropriate data to meet the needs of the more sophisticated studies. It is suggested that a Bayesian approach be utilized to develop a final risk model based upon measurement of prior observations from the Phase I studies and the set of posterior observations that would be obtained from whichever chronic study is conducted.

Animals↗

Bromate-induced ototoxicity.

For decades, it has been known that ingested potassium bromate and sodium bromate can induce hearing loss. Hearing loss onset, following high-dose ingestion, is generally rapid occurring within 4-16 h and of a severe to profound degree. Unlike the sensorineural hearing loss which is generally irreversible, bromate-induced tinnitus, which is less well-studied, may reportedly be permanent or temporary. It is not clear whether actual bromate-induced vestibulotoxicity occurs in clinical populations. The primary sites of lesion for bromate-induced ototoxicity appear to be in the cochlea. However, possible effects on the VIIIth nerve and central auditory system have not been fully investigated. Based on animal studies, in the cochlea, bromate damages the stria vascularis, Reissner's membrane, inner and outer hair cells, Claudius cells and inner sulcus cells. Physiologically, bromate reduces the endocochlear potential, cochlear microphonics, and electrophysiologic auditory thresholds. Possible mechanisms are discussed. The effects of long-term low-dose bromate exposure on hearing have not been studied. These effects, if they occur, may not be readily detected in many clinical populations, because idiopathic hearing loss occurs commonly in the population as a whole. Further it is unknown whether or not chronic bromate ingestion may exacerbate noise-induced hearing loss. Further study to determine the maximum safe exposure level for long-term administration and to develop possible antidotes is warranted.

Animals↗

Mutagenicity of bromate: implications for cancer risk assessment.

Bromate (BrO3-) is a rodent carcinogen that is formed as a drinking water ozone disinfection by-product and also used in some food and consumer products. Therefore, bromate is subject to assessment for its risk to humans. Because the selection of an appropriate model for conducting quantitative cancer risk assessment is based upon an understanding of the chemical's mode-of-action, it is necessary to determine whether the chemical is a mutagenic carcinogen. We present a review of the available information concerning the weight-of-the-evidence that bromate is a mutagenic carcinogen. The evidence indicates that bromate is mutagenic and that this activity is mediated by the formation of oxidative damage to the DNA, thus resulting in chromosomal damage. Not only does bromate induce genetic damage in vitro, it is also demonstrated to induce mutations in the kidney of exposed rats. This is significant because the rat kidney is one of the target tissues for tumor induction. While it is clear that bromate can cause damage in the target tissue, it is not clear whether bromate is a mutagenic carcinogen, that is, whether the observed tumors result from a mutagenic mode-of-action. Further research is needed to clarify bromate's mode-of-action. However, in the absence of additional information, it is reasonable, based on an extensive database, to assume that bromate induces tumors via oxidative damage that causes chromosomal breakage.

Animals↗

Role of humic acid and ouinone model compounds in bromate reduction by zerovalent iron.

Experiments were conducted to examine the role of humic acid and quinone model compounds in bromate reduction by Fe(0). The reactivity of Fe(0) toward bromate declined by a factor of 1.3-2.0 in the presence of humic acid. Evidence was obtained that the quick complexation of humic acid with iron species and its adsorption passivated the iron surface and decreased the rate of bromate reduction by Fe(0). On the other hand, in the long run, the reduced functional groups present in humic acid were observed to regenerate Fe(II) and reduce bromate abiotically. Compared with the case of humic acid only, the simultaneous presence of Fe(II) and humic acid significantly increased the bromate removal rate. Fe(III)/Fe(II) acted as a catalyst in the oxidation of humic acid by bromate. Anthraquinone-2,6-disulfonate (AQDS) and lawsone did not cause any significant effect on the bromate reduction rate by Fe(0). However, the redox reactivity of lawsone in the presence of Fe(III) was evident, while AQDS did not show any under the tested conditions. The difference was attributable to the presence/ absence of reducing functional groups in the model compounds. The electron spin resonance further demonstrated that the redox functional groups in humic acid are most likely quinone-phenol moieties. Although the bromate reduction rate by regenerated Fe(II) is a few times slower than that by Fe(0), the reactive Fe(II) can be, alternatively, reductively formed to maintain iron surface activation and bromate reduction to prolong the lifetime of the zerovalent iron.

Adsorption↗